Kousai Bio DC Vaccine for Pancreatic Cancer Program Officially Launched

October 21, 2025 84

On October 21st, 2025, the Cancer Hospital of Fudan University held a kick-off meeting for the project "KSD-301 in combination with AG regimen (Gemcitabine, Albumin Paclitaxel) for the treatment of locally advanced unresectable pancreatic cancer". The project is led by Prof. Xianjun Yu, President of the Affiliated Cancer Hospital of Fudan University and Director of the Institute of Pancreatic Tumor Research of Shanghai and Fudan University, as the principal investigator, and the investigational drug KSD-301 is Hengsai's...

View details